ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.830
+0.080 (4.57%)
Jan 17, 2025, 4:00 PM EST - Market closed
ADC Therapeutics Employees
As of December 31, 2023, ADC Therapeutics had 274 total employees, including 273 full-time and 1 part-time employees. The number of employees decreased by 43 or -13.56% compared to the previous year.
Employees
274
Change (1Y)
-43
Growth (1Y)
-13.56%
Revenue / Employee
$258,091
Profits / Employee
-$774,270
Market Cap
176.94M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 274 | -43 | -13.56% |
Dec 31, 2022 | 317 | 5 | 1.60% |
Dec 31, 2021 | 312 | 104 | 50.00% |
Dec 31, 2020 | 208 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ADCT News
- 18 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 21 days ago - ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PRNewsWire
- 5 weeks ago - ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL - Seeking Alpha
- 5 weeks ago - ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PRNewsWire
- 6 weeks ago - ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - PRNewsWire
- 6 weeks ago - ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - PRNewsWire
- 2 months ago - ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why - Benzinga